Abstract
Neuroblastoma is the most common extracranial solid tumor in childhood. Despite intense multimodal therapy and many improvements through basic scientific and clinical research, the successful response of advanced-stage patients to chemotherapy remains poor. Autophagy is a cytoprotective mechanism that may help advanced cancer cells survive stressful conditions such as chemotherapy. Here we review our recent findings describing HDAC10 as a promoter of autophagy-mediated survival in neuroblastoma cells and identifying this HDAC isozyme as a druggable regulator of advanced-stage tumor cell survival. These results propose a new and promising way to considerably improve treatment response in the neuroblastoma patient subgroup with the poorest outcome.
Original language | English (US) |
---|---|
Pages (from-to) | 2163-2165 |
Number of pages | 3 |
Journal | Autophagy |
Volume | 9 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2013 |
Externally published | Yes |
Keywords
- Drug resistance
- HDAC-inhibitor
- HDAC10
- Lysosome
- Macroautophagy
- Neuroblastoma
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology